Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial

初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字治疗：混合 III 型实施试验

• 批准号: 10092143
• 负责人: Joseph Edwin Glass
• 金额: $ 69万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10092143
• 关键词: Abstinence; Academy; Address; Adopted; Adoption; Behavioral; Buprenorphine; Caring; Cellular Phone; Clinic; Cognitive; Cognitive Therapy; Data; Dose; Drug usage; Effectiveness; Ensure; Epidemic; FDA approved; Face; Health system; Healthcare; Human; Hybrids; Individual; Intervention; Knowledge; Laboratories; Learning; Life; Literature; Medical; Medicine; Methods; Modeling; Observational Study; Opioid; Patient Care; Patients; Pear; Population; Primary Health Care; Randomized; Randomized Controlled Trials; Research Design; Research Personnel; Running; Savings; Substance Use Disorder; Symptoms; System; Testing; Therapeutic; Traction; United States Food and Drug Administration; Visit; Washington; alcohol use disorder; base; behavioral health; buprenorphine treatment; care systems; compare effectiveness; computerized; cost; cost effectiveness; design; digital; digital health; digital treatment; effective intervention; effective therapy; effectiveness implementation study; evidence base; formative assessment; implementation barriers; implementation cost; implementation science; implementation strategy; implementation trial; improved; innovation; instrument; novel strategies; opioid mortality; opioid use disorder; population based; psychosocial; screening; smartphone Application; substance use; success

PROJECT SUMMARY The proposed study addresses a critical knowledge gap: How to best implement digital treatments for opioids and other substance use disorders (SUDs) in primary care (PC). In 2017, the US Food and Drug Administration approved the first ever digital therapeutic for any medical condition. The therapeutic is reSET, a smartphone-based version of the Therapeutic Educational System, which is a computerized cognitive- behavioral treatment for SUDs. We will study implementation of reSET into PC to potentially improve care for people with SUDs, and as a model for how to sustainably implement digital treatments into real-world healthcare. Digital treatments could extend the reach of SUD therapy to more people and could address the lack of access to psychosocial treatment, a significant barrier to buprenorphine prescribing (a life-saving treatment for opioid use disorders [OUD]) in PC. A prior implementation trial found that a digital SUD treatment in PC was not sustained in part because of workflow and cost burdens so our study design and analytic plan focus on these issues. Our delivery system partners in Kaiser Permanente Washington are committed to collaborating with us to study strategies for implementing reSET in 25 PC clinics in Washington State and to address prior implementation challenges documented in the literature. After piloting in 2 clinics, we will randomize 23 clinics in a 2x2 factorial design to four approaches: (1) “standard implementation,” which is an evidence-based implementation strategy previously used by our delivery system partners; (2) “standard implementation with external facilitation,” a clinician-facing implementation strategy; (3) “standard implementation with patient coach,” a patient-facing implementation strategy using medical assistants to support patient adoption and engagement; and (4) “standard implementation with both.” These implementation strategies have some evidence in PC, but their impact on real-world implementation of a digital treatment has not been evaluated. Specific Aims are to (1) Estimate the effect of clinician-facing (external facilitation) and patient-facing (patient coach) implementation strategies in increasing the reach and fidelity of a digital SUD treatment in PC clinics, and (2) compare the population-level cost-effectiveness of each implementation strategy in increasing reach, fidelity, and abstinence by patients. IMPACT: Researchers and health systems do not know how to reach large numbers of patients with OUDs and other SUDs. Digital treatments are promising, but health systems lack evidence to guide implementation of digital therapies. This study will estimate and compare the effectiveness of clinician-facing and patient-facing implementation strategies, providing health system leaders with data on how to best implement digital treatments.

项目总结 这项拟议的研究解决了一个关键的知识缺口：如何最好地实施数字化治疗 初级保健(PC)中的阿片类药物和其他物质使用障碍(SODS)。2017年，美国食品和药物管理局 政府批准了有史以来第一个针对任何医疗条件的数字治疗。治疗被重置，一个 基于智能手机的治疗教育系统版本，这是一个计算机化的认知系统- 肥皂泡的行为治疗。我们将研究在PC中实施重置，以潜在地改善对 患有肥皂泡的人，并作为如何可持续地将数字治疗应用于现实世界的典范 医疗保健。数字化治疗可以将SUD治疗的覆盖范围扩大到更多的人，并可以解决 缺乏获得心理社会治疗的机会，丁丙诺啡处方的一个重大障碍(一种救命药物 治疗阿片类药物使用障碍[OUD])。先前的实施试验发现，数字SUD治疗 由于工作流程和成本负担，在PC中没有得到支持，所以我们的研究设计和分析方案 关注这些问题。我们在凯撒永久华盛顿的交付系统合作伙伴致力于 与我们合作研究在华盛顿州25个PC诊所实施Reset的策略，并 解决文献中记录的先前实施挑战。在两家诊所试行后，我们将 用2x2析因设计将23个诊所随机分为四种方法：(1)“标准实施”，这是一种 我们的交付系统合作伙伴以前使用的循证实施战略；(2)“标准 外部促进实施，《面向临床医生的实施策略；(3)》标准 实施与患者教练，“一种面向患者的实施战略，使用医疗助理 支持患者采用和参与；以及(4)“两者兼而有之”。这些实施 策略在PC中有一些证据，但它们对数字治疗的现实世界实施的影响已经 没有经过评估。具体目标是(1)评估面向临床医生(外部促进)和 面向患者(患者指导)的实施策略，以提高数字SUD的覆盖范围和保真度 PC诊所的治疗，以及(2)比较每项实施的人口水平成本效益 增加患者伸展范围、忠诚度和禁欲的策略。影响：研究人员和卫生系统做到了 不知道如何接触到大量患有尿毒症和其他肥皂水的患者。数字化治疗是 很有希望，但卫生系统缺乏证据来指导数字疗法的实施。这项研究将 评估和比较面向临床医生和面向患者的实施策略的有效性， 为卫生系统领导人提供关于如何最好地实施数字治疗的数据。